Jamal Misleh

677 total citations
24 papers, 204 citations indexed

About

Jamal Misleh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jamal Misleh has authored 24 papers receiving a total of 204 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jamal Misleh's work include Lung Cancer Research Studies (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer-related cognitive impairment studies (3 papers). Jamal Misleh is often cited by papers focused on Lung Cancer Research Studies (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer-related cognitive impairment studies (3 papers). Jamal Misleh collaborates with scholars based in United States, China and Switzerland. Jamal Misleh's co-authors include Michelle C. Janelsins, Supriya G. Mohile, Lianlian Lei, Adedayo A. Onitilo, Song Liu, Nancy P. Blumenthal, Stephen J. Schuster, Nikesha Gilmore, Qiang Hu and Edward A. Stadtmauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jamal Misleh

22 papers receiving 204 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jamal Misleh	93	63	48	38	37	24	204
Ali Abdulnabi Suwaidan	118 1.3×	52 0.8×	43 0.9×	25 0.7×	47 1.3×	13	234
Rik J. Verheijden	254 2.7×	68 1.1×	44 0.9×	17 0.4×	16 0.4×	22	304
Claire Forde	50 0.5×	56 0.9×	69 1.4×	13 0.3×	11 0.3×	22	203
Gustav Magrinat	120 1.3×	54 0.9×	15 0.3×	16 0.4×	13 0.4×	10	184
Hussein Awada	64 0.7×	18 0.3×	87 1.8×	19 0.5×	39 1.1×	41	223
Regina Gironés Sarrió	81 0.9×	73 1.2×	20 0.4×	17 0.4×	12 0.3×	28	161
Cristina Morelli	125 1.3×	53 0.8×	34 0.7×	42 1.1×	7 0.2×	23	201
Andrew Johns	163 1.8×	61 1.0×	46 1.0×	7 0.2×	17 0.5×	33	243
Francesco Cortiula	202 2.2×	170 2.7×	51 1.1×	21 0.6×	13 0.4×	38	324
D. Purdie	116 1.2×	52 0.8×	32 0.7×	14 0.4×	8 0.2×	23	214

Countries citing papers authored by Jamal Misleh

Since Specialization

Citations

This map shows the geographic impact of Jamal Misleh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamal Misleh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamal Misleh more than expected).

Fields of papers citing papers by Jamal Misleh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamal Misleh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamal Misleh. The network helps show where Jamal Misleh may publish in the future.

Co-authorship network of co-authors of Jamal Misleh

This figure shows the co-authorship network connecting the top 25 collaborators of Jamal Misleh. A scholar is included among the top collaborators of Jamal Misleh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamal Misleh. Jamal Misleh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharman, Jeff P., Aung M. Tun, José C. Villasboas, et al.. (2025). Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study. Blood. 146(Supplement 1). 62–62.

Shadman, Mazyar, John M. Burke, Jennifer L. Cultrera, et al.. (2025). Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. Blood Advances. 9(16). 4100–4110. 4 indexed citations

Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations

Zhao, Tianming, James D. Bearden, Benjamin Esparaz, et al.. (2025). Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy. JNCI Cancer Spectrum. 9(6).

Adkins, Douglas R., Jamal Misleh, Jochen H. Lorch, et al.. (2025). Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 43(16_suppl). 6048–6048. 1 indexed citations

Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2024). A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. European Journal of Cancer. 201. 113950–113950. 2 indexed citations

Marron, Thomas U., Zev A. Wainberg, Alexander I. Spira, et al.. (2024). Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2597–2597. 1 indexed citations

Enzler, Thomas, Anna Nguyen, Jamal Misleh, et al.. (2023). 1625P Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for ≥ third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3. Annals of Oncology. 34. S900–S900. 2 indexed citations

Hendifar, Andrew, David R. Spigel, Donald Richards, et al.. (2023). 646P Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC). Annals of Oncology. 34. S454–S455. 3 indexed citations

10.

Shadman, Mazyar, Jeff P. Sharman, Moshe Levy, et al.. (2020). Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib. Blood. 136(Supplement 1). 51–52. 3 indexed citations

11.

Yao, Song, Qiang Hu, Sarah L. Kerns, et al.. (2019). Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study. Clinical Epigenetics. 11(1). 45–45. 35 indexed citations

12.

Magnuson, Allison, Lianlian Lei, Nikesha Gilmore, et al.. (2019). Longitudinal Relationship Between Frailty and Cognition in Patients 50 Years and Older with Breast Cancer. Journal of the American Geriatrics Society. 67(5). 928–936. 42 indexed citations

13.

Masters, Gregory A., David D. Biggs, Charles Schneider, et al.. (2018). Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer. Cancer Medicine. 7(7). 2969–2973. 1 indexed citations

14.

Magnuson, Allison, Supriya G. Mohile, Lianlian Lei, et al.. (2017). Longitudinal trajectory of frailty and related factors in 376 breast cancer patients aged 50+ compared to controls.. Journal of Clinical Oncology. 35(15_suppl). e21532–e21532. 1 indexed citations

15.

Sanborn, Rachel E., Jyoti D. Patel, Gregory A. Masters, et al.. (2016). A randomized, double‐blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive‐stage small cell lung cancer: Hoosier Cancer Research Network LUN06‐113. Cancer. 123(2). 303–311. 26 indexed citations

16.

Witzig, Thomas E., Michael Tomblyn, Jamal Misleh, et al.. (2014). Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 99(11). 1738–1745. 19 indexed citations

17.

Sanborn, Rachel E., Jyoti D. Patel, Gregory A. Masters, et al.. (2014). A randomized double-blind phase II trial of platinum (P) plus etoposide (E) with or without concurrent ZD6474 (Z) in patients (pts) with previously untreated extensive-stage (ES) small cell lung cancer (SCLC): Hoosier Oncology Group LUN06-113.. Journal of Clinical Oncology. 32(15_suppl). 7506–7506. 1 indexed citations

18.

Misleh, Jamal, et al.. (2013). Multidisciplinary Management of Gastric Cancer. Surgical Oncology Clinics of North America. 22(2). 247–264. 10 indexed citations

19.

Kremer, Brandon E., Ran Reshef, Jamal Misleh, et al.. (2011). Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases. The Journal of Heart and Lung Transplantation. 31(3). 296–304. 35 indexed citations

20.

Misleh, Jamal, Vivek N. Ahya, James H. Christie, et al.. (2008). Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients. Journal of Clinical Oncology. 26(15_suppl). 19521–19521. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact